There remains considerable controversy over the effectiveness and ethics of prescribing medication to children with Attention Deficit Hyperactivity Disorder (ADHD). The U.S. Food and Drug Administration has approved a 30-minute onset of action for a drug called Focalin XR which will allow the manufacturers, Novartis, to claim that the drug takes effect within this time. The move is based on clinical data, including a study of 86 children aged between 6 and 12.
You can find out more about this story at
http://www.mentalhelp.net/poc/view_doc.php?type=news&id=114591&cn=3
-
Posts
No comments:
Post a Comment